4-Cholesten-3-one

4-Cholesten-3-one is a lipid of Sterol Lipids (ST) class. 4-cholesten-3-one is associated with abnormalities such as Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana and Xanthoma. The involved functions are known as CYP27A1activity, 25-hydroxycholesterol 7alpha-hydroxylase activity, Biochemical Pathway, Anabolism and Oxidation. 4-cholesten-3-one often locates in Mitochondria, Liver, Body tissue, Hepatic, Mitochondria and Endothelium of artery. The associated genes with 4-Cholesten-3-one are P4HTM gene, tryptones and Regulon. The related lipids are Cholestenones, 7-hydroxy-4-cholesten-3-one, cholest-4-en-3-one, 25-hydroxycholesterol and 24-hydroxycholesterol.

Cross Reference

Introduction

To understand associated biological information of 4-Cholesten-3-one, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 4-Cholesten-3-one?

4-Cholesten-3-one is suspected in Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana, Xanthoma, Rare Diseases and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

No disease MeSH terms mapped to the current reference collection.

PubChem Associated disorders and diseases

What pathways are associated with 4-Cholesten-3-one

Lipid pathways are not clear in current pathway databases. We organized associated pathways with 4-Cholesten-3-one through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 4-Cholesten-3-one?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 4-Cholesten-3-one?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 4-Cholesten-3-one?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 4-Cholesten-3-one?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 4-Cholesten-3-one?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 4-Cholesten-3-one

Download all related citations
Per page 10 20 50 100 | Total 397
Authors Title Published Journal PubMed Link
Carneiro MM et al. Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis. 2008 BJOG pmid:17983420
Thevis M et al. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. 2007 Ther Drug Monit pmid:17417080
Petraki CD and Sfikas CP Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. 2007 Histol. Histopathol. pmid:17128417
Prayer-Galetti T Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. 2007 Eur. Urol. pmid:17448594
Cussenot O et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. 2007 Eur. Urol. pmid:17448593
Maier C Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. 2007 Eur. Urol. pmid:17448591
Morgentaler A Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. 2007 J. Urol. pmid:17437855
Chai TC Treatment of men with lower urinary tract symptoms and overactive bladder. 2007 JAMA pmid:17374808
García CI et al. Differential gene expression during development in two oligodendroglial cell lines overexpressing transferrin: a cDNA array analysis. 2007 Dev. Neurosci. pmid:17119318
Seiffert K et al. Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. 2007 Horm. Metab. Res. pmid:17326010